Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test.

BACKGROUND Many people who use hypnotics are outpatients and are likely to drive a car the day after drug intake. The purpose of these meta-analyses was to determine whether or not this is safe. METHODS Placebo-controlled, randomized, double-blind trials were selected if using the on-the-road driving test to determine driving ability the day following one or two nights of treatment administration. Primary outcome measure of the driving test was the Standard Deviation of Lateral Position (SDLP); i.e., the weaving of the car. Fixed effects model meta-analyses were performed. Effect size (ES) was computed using mean standardized (weighted) difference scores between treatment and corresponding placebo SDLP values. RESULTS Ten studies, published from 1984 to 2002 (207 subjects), were included in the meta-analyses. The morning following bedtime administration, i.e. 10-11 hours after dosing, significant driving impairment was found for the recommended dose of various benzodiazepine hypnotics (ES=0.42; 95% Confidence Interval (CI)=0.14 to 0.71). Twice the recommended dose impaired driving both in the morning (ES=0.68; CI=0.39 to 0.97) and afternoon, i.e. 16-17 hours after dosing (ES=0.57; CI=0.26 to 0.88). Zopiclone 7.5 mg also impaired driving in the morning (ES=0.89; CI=0.54 to 1.23). Zaleplon (10 and 20 mg) and zolpidem (10 mg) did not affect driving performance the morning after dosing. Following middle-of-the-night administration, significantly impaired driving performance was found for zopiclone 7.5 mg (ES=1.51, CI=0.85 to 2.17), zolpidem 10 mg (ES=0.66, CI=0.13 to 1.19) and zolpidem 20 mg (ES=1.16, CI=0.60 to 1.72). Zaleplon (10 and 20 mg) did not affect driving performance. CONCLUSIONS The analyses show that driving a car the morning following nocturnal treatment with benzodiazepines and zopiclone is unsafe, whereas the recommended dose of zolpidem (10 mg) and zaleplon (10 mg) do not affect driving ability.

[1]  Jørg Mørland,et al.  Clinical impairment of benzodiazepines--relation between benzodiazepine concentrations and impairment in apprehended drivers. , 2002, Drug and alcohol dependence.

[2]  S. Ancoli-Israel,et al.  Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. II. , 1999, Sleep.

[3]  S. Ancoli-Israel,et al.  Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. , 1999, Sleep.

[4]  R. Sims,et al.  Relations among chronic medical conditions, medications, and automobile crashes in the elderly: a population-based case-control study. , 2000, American journal of epidemiology.

[5]  Mark W. Lipsey,et al.  Practical Meta-Analysis , 2000 .

[6]  J F O'Hanlon,et al.  Diazepam impairs lateral position control in highway driving. , 1982, Science.

[7]  Joris C Verster,et al.  Residual Effects of Middle-of-the-Night Administration of Zaleplon and Zolpidem on Driving Ability, Memory Functions, and Psychomotor Performance , 2002, Journal of clinical psychopharmacology.

[8]  K. Brookhuis,et al.  Repeated dose effects of lormetazepam and flurazepam upon driving performance , 2007, European Journal of Clinical Pharmacology.

[9]  J. Verster,et al.  Residual effects of sleep medication on driving ability. , 2004, Sleep medicine reviews.

[10]  K. Brookhuis,et al.  Repeated dose effects of nitrazepam and temazepam upon actual driving performance , 1985 .

[11]  W A Ray,et al.  Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. , 1992, American journal of epidemiology.

[12]  A. Vermeeren,et al.  Residual effects of evening and middle‐of‐the‐night administration of zaleplon 10 and 20 mg on memory and actual driving performance , 1998 .

[13]  B. Hemmelgarn,et al.  Benzodiazepine use and the risk of motor vehicle crash in the elderly. , 1997, JAMA.

[14]  C. I. Neutel,et al.  Risk of traffic accident injury after a prescription for a benzodiazepine. , 1995, Annals of epidemiology.

[15]  J. O'hanlon,et al.  DRIVING PERFORMANCE THE DAY AFTER THE USE OF LOPRAZOLAM, FLUNITRAZEPAM AND PLACEBO , 1984 .

[16]  E. Volkerts,et al.  A comparative study of on‐the‐road and simulated driving performance after nocturnal treatment with lormetazepam 1 mg and oxazepam 50 mg , 1992 .

[17]  W. Riedel,et al.  Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. , 2002, Sleep.

[18]  Edmund R. Volkerts,et al.  Driving and Benzodiazepine Use , 1998 .

[19]  M C Longo,et al.  The relationship between blood benzodiazepine concentration and vehicle crash culpability , 2001 .

[20]  Annemiek Vermeeren,et al.  Residual Effects of Hypnotics , 2004, CNS drugs.

[21]  Suzanne G. Leveille,et al.  Psychoactive Medications and Injurious Motor Vehicle Collisions Involving Older Drivers , 1994, Epidemiology.

[22]  Karel Brookhuis,et al.  Zopiclone's residual effect upon actual driving performance versus those of nitrazepam and flunitrazepam , 1984 .

[23]  E. Volkerts,et al.  A DOUBLE-BLIND STUDY TO COMPARE THE ACUTE RESIDUAL EFFECTS OF LORMETAZEPAM 1 MG, OXAZEPAM 50 MG AND PLACEBO ON DRIVING PERFORMANCE IN AN OVER-THE-ROAD DRIVING TEST , 1989 .

[24]  J. O'hanlon,et al.  Driving performance under the influence of drugs: rationale for, and application of, a new test. , 1984, British journal of clinical pharmacology.

[25]  A. Declerck,et al.  Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo , 1995 .

[26]  U. Rudolph,et al.  Mechanism of action of the hypnotic zolpidem in vivo , 2000, British journal of pharmacology.

[27]  G. Biggio,et al.  Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. , 2002, European journal of pharmacology.

[28]  F. Barbone,et al.  Association of road-traffic accidents with benzodiazepine use , 1998, The Lancet.